Key points are not available for this paper at this time.
This cohort study compares glucagon-like peptide 1 receptor agonists (GLP-1RAs) with 7 non–GLP-1RA antidiabetics among drug-naive patients with type 2 diabetes.
Wang et al. (Thu,) studied this question.